Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of:...Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.

Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Cervical cancer: Systemic therapy for cervical cancer…squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma…recurrent or metastatic disease…second-line therapy…other recommended regimens…bevacizumab

Cervical cancer: Systemic therapy for cervical cancer…squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma…recurrent or metastatic disease…first-line combination therapy…preferred regimens…cisplatin/paclitaxel/bevacizumab…carboplatin/paclitaxel/bevacizumab...other recommended regimens…topotecan/paclitaxel/bevacizumab…

The GOG 240 study reported a 3.7-month survival benefit with the addition of bevacizumab to the combination chemotherapy regimen in patients with advanced or recurrent cervical cancer. The Expert Panel recommends the inclusion of this agent with carboplatin or cisplatin and paclitaxel combination in maximal settings, with careful attention to potential toxicities of this regimen.

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival.